Genmab — April 2019

[kkjoel]

They keep popping up... those small pieces of good news, don't they? Hard to keep pessimisticism!

[JKY_VH]

tak E L

[peter12]

AQR har reduceret til 1,88% dvs 0,11% ?

[peter12]

I går

[Doc4]

Her lidt om omkostninger for Dara kombier...RESULTS:
The estimated cost per patient for each triplet regimen was $13,890 (DARA/BOR/DEX), $22,231 (IXA/LEN/DEX), $24,322 (ELO/LEN/DEX), $26,410 (DARA/LEN/DEX), and $27,432 (CAR/LEN/DEX). Drug acquisition costs and treatment duration were the largest drivers of cost. https://www.ncbi.nlm.nih.gov/pubmed/30917078

[Doc4]

Single-agent daratumumab in very advanced relapsed and refractory multiple myeloma patients: a real-life single-center retros.These real-life results revealed modest efficacy of single-agent daratumumab in advanced patients with RRMM in comparison with data from clinical trials. The overall response rate was 24%, including 5% very good partial response or better. After a median follow-up of 6.5 months, all patients experienced disease relapse. The median progression-free survival was 1.9 mo.

[Doc4]

https://www.ncbi.nlm.nih.gov/pubmed/30874850

[peter12]

"Most patients presented with high-risk characteristics", så det er vel ikke en normal gruppe ?

[Bulder]

Lidt ringere end Sirius. 24% ORR vs 29% og median PFS 1,9 md vs. 3,7 md. Median antal forudgående behandlinger 4 vs 5. Om patienterne iøvrigt er sammenlignelige ved jeg ikke. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)01120-4/fulltext

[bibob]

Det er jo ikke kun Genmab. Markedet afventer nogle nøgletal i slut ugen. Faldet har ikke noget med hverken dårlige eller gode nyheder at gøre ift Genmab.

[Bulder]

Vi må håbe at Car-t kommer ind her med noget bedre når dara/imid kombierne er udtømte.

[Helge_LarsenPI-redaktør]

Enig bibob . Alt ser rød ud her hos mig.

[Helge_LarsenPI-redaktør]

Ham her er ikke ked af det. https://play.borsen.dk/social/5cac6c6e595ab4f00a3311e8

[Doc4]

T-cell acute lymphoblastic leukaemia (T-ALL) - “Dar”-ing to target CD38 in T-ALL. T-cell acute lymphoblastic leukemia = T-ALL. ..."This study is compelling because it provides strong evidence that daratumumab should have clinical efficacy in T-ALL"

[Doc4]

(www.bloodjournal.org)

[transalp]

Øhhe det lyder ret positivt Doc4, den smule som lægmand forstår.. tak for link..

[jkj]

Ifølge FDA,s tidsplan for RTOR, så bør godkendelse af Dara til 1 Linje komme i indeværende uge.

[bibob]

Fredag efter luk.

[JKY_VH]

Det glæder vi os til;-)

[Schiff]

@pensionisten jeg synes faktisk ikke man kan sige at Genmab har klaret sig specielt godt YTD når man ser på resten
af den eurofori der har været i C25.